Celularity Inc (CELU) FinancialsCELUFinancialCelularity Inc

Celularity Inc (CELU) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Degenerative Disease, accounting for 64.5% of total sales, equivalent to $3.70M. Other significant revenue streams include BioBanking and Cell Therapy. Understanding this composition is critical for investors evaluating how CELU navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Celularity Inc maintains a gross margin of -88.86%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -537.48%, while the net margin is -593.62%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively CELU converts its operational activities into shareholder value.

In the context of the broader market, CELU competes directly with industry leaders such as AHMA and ACCL. With a market capitalization of $45.73M, it holds a significant position in the sector. When comparing efficiency, CELU's gross margin of -88.86% stands against AHMA's 24.86% and ACCL's 39.29%. Such benchmarking helps identify whether Celularity Inc is trading at a premium or discount relative to its financial performance.

Celularity's financial performance shows a gross margin of 65.67% in Q1 2025, but it has been inconsistent, with a negative net income of -24,446,000 USD in Q4 2025. The company has struggled with profitability, as evidenced by its negative EPS of -0.86 in Q4 2025.